Back to Report Store Home

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • Published: Sep-2017
  • Report Code: GBIHC455MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Overview

2.2 Classification of Diabetes

2.3 Symptoms

2.4 Diagnostic Criteria

2.5 Etiology

2.5.1 T1DM

2.5.2 T2DM

2.6 Pathophysiology

2.6.1 Physiology of Glucose Metabolism

2.6.2 T1DM Pathophysiology

2.6.3 T2DM Pathophysiology

2.7 Epidemiology

2.7.1 T1DM

2.7.2 T2DM

2.8 Comorbidities and Complications

2.9 Treatments

2.9.1 Insulin Therapy

2.9.2 Insulin Secretagogues

2.9.3 Thiazolidinediones

2.9.4 Biguanides

2.9.5 Dipeptidyl Peptidase 4 Inhibitors

2.9.6 Glucagon-Like Peptide-1 Receptor Agonists

2.9.7 Sodium–Glucose Co-Transporter-2 Inhibitors

2.9.8 Amylin Analogs

2.9.9 Combination Therapies

2.9.10 Non-pharmacological Therapy

3 Key Marketed Products

3.1 Overview

3.1.1 Market Share of the Top Five Grossing Drugs in 2016

3.1.2 Market Share of the Five Strongest Growing Blockbuster Drugs

3.2 Long-Acting Insulin Therapies (Basal Insulins)

3.2.1 Lantus (insulin glargine) – Sanofi

3.2.2 Levemir (insulin detemir) – Novo Nordisk

3.2.3 Tresiba (insulin degludec) – Novo Nordisk

3.2.4 Toujeo (insulin glargine) – Sanofi

3.3 Short-Acting Insulin Therapies (Bolus Insulins)

3.3.1 Humalog (insulin lispro) – Eli Lilly

3.3.2 Novolog (Insulin aspart) – Novo Nordisk

3.3.3 Apidra (insulin glulisine) – Sanofi

3.4 GLP-1 Receptor Agonists

3.4.1 Victoza (liraglutide) – Novo Nordisk

3.4.2 Trulicity (dulaglutide) – Eli Lilly

3.5 DPP-4 Inhibitors

3.5.1 Januvia (sitagliptin) – Merck and Co

3.5.2 Galvus (vildagliptin) – Novartis

3.5.3 Tradjenta (linagliptin) – Boehringer Ingelheim

3.6 SGLT-2 Inhibitors

3.6.1 Invokana (canagliflozin) – Johnson and Johnson

3.6.2 Jardiance (empagliflozin) - Boehringer Ingelheim

3.6.3 Farxiga (dapagliflozin) – AstraZeneca

3.7 Combination Therapies

3.7.1 Soliqua 100/33 (insulin glargine and lixisenatide) – Sanofi

3.7.2 Xultophy (insulin degludec and liraglutide) – Novo Nordisk

3.7.3 Janumet – Merck

3.7.4 Qtern (saxagliptin and dapagliflozin) – AstraZeneca

3.8 Unmet Needs

3.9 Conclusion

4 Pipeline Landscape Assessment

4.1 Overview

4.2 Pipeline Development Landscape

4.3 Molecular Targets in the Pipeline

4.4 Clinical Trials Landscape

4.4.1 Clinical Trial Failure Rates

4.4.2 Clinical Trial Duration

4.4.3 Clinical Trial Size

4.4.4 Aggregate Clinical Program Size

4.5 Assessment of Key Pipeline Products

4.5.1 Semaglutide (NN-9535) – Novo Nordisk

4.5.2 Oral Semaglutide (OG-217SC) – Novo Nordisk

4.5.3 ITCA 650 – Intarcia

4.5.4 Sotagliflozin – Lexicon Pharmaceuticals and Sanofi

4.5.5 Ertugliflozin – Merck and Co and Pfizer

5 Multi-scenario Market Forecast to 2023

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target

5.3.1 Insulin Receptors

5.3.2 GLP-1 Receptors

5.3.3 SGLT-2 Inhibitors

5.3.4 DPP-4 Inhibitors

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 Novo Nordisk – Sales from Recently Approved and Upcoming Products to Increase Already Substantial Market Share

6.1.2 Eli Lilly – Strong Growth to Result in Elevation to Second Place in Market

6.1.3 Sanofi – Large Market Share Loss Due to Declining Sales of Lantus

6.1.4 AstraZeneca – Growth in Revenue Largely Attributable to Farxiga Sales

6.1.5 Johnson and Johnson – Continued Uptake of Invokana to Drive Market Growth

6.1.6 Merck & Co – Patent Expiry of Januvia to Limit Growth

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing deals

7.1.1 Deals by Region, Value and Year

7.1.2 Deals by Stage of Development and Value

7.1.3 Deals by Molecule Type and Molecular Target

7.1.4 Licensing Deals Valued at $100m or above

7.2 Co-Development Deals

7.2.1 Deals by Region, Value and Year

7.2.2 Deals by Stage of Development and Value

7.2.3 Deals by Molecule Type and Molecular Target

7.2.4 Co-development Deals Valued at $100m and above

8 Appendix

8.1 References

8.2 Abbreviations

8.3 List of All Pipeline Products

8.4 Disease List

8.5 Methodology

8.5.1 Coverage

8.5.2 Secondary Research

8.5.3 Market Size and Revenue Forecasts

8.5.4 Pipeline Analysis

8.5.5 Competitive Landscape

8.6 Contact Us

8.7 Disclaimer

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards